Investing.com - Financial Markets Worldwide
Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Valeant to buy ophthalmic surgical device maker Synergetics

Published 2015-09-02, 09:00 a/m
© Reuters. Valeant to buy ophthalmic surgical device maker Synergetics
BHC
-
SURG_old
-

Sept 2 (Reuters) - Canada's Valeant Pharmaceuticals (NYSE:VRX)
International Inc VRX.TO VRX.N agreed to buy surgical device
maker Synergetics USA Inc SURG.O , its eighth acquisition this
year.
Valent said on Wednesday it would commence a tender offer to
acquire all outstanding shares of Synergetics for $6.50 per
share, a premium of 48 percent to Synergetics' Tuesday close on
the Nasdaq.
Shares of Synergetics, which makes surgical devices for
ophthalmology and neurosurgery, were trading at $6.68 before the
bell.
At $6.50, the offer was worth about $166 million based on
Synergetics' diluted outstanding shares as of April 30.
The acquisition, which is expected to close in the fourth
quarter, is aimed at expanding the Bausch + Lomb's business, the
company said. Valeant bought the company for $8.7 billion in
2013.
The Synergetics offer comes less than two weeks after
Valeant bought Sprout Pharmaceuticals, which makes a
controversial new drug to treat low sexual desire in women, for
about $1 billion.
Synergetics shareholders will receive additional cash
payments of up to $1 per share if certain sales milestones are
reached after the transaction closes, Valeant said.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.